CELLTRION HEALTHCARE IRELAND LIMITED

Celltrion Healthcare Ireland Limited is the Irish arm of Celltrion, a global biopharmaceutical leader that offers a complete, end-to-end solution for the development and commercialisation of biologic medicines. From early-stage research and development through clinical trials, regulatory approval, large-scale manufacturing and worldwide distribution, the company provides a single point of contact for partners seeking high-quality, cost-effective therapeutics.

The group operates Korea's largest integrated R&D centre, a US FDA- and EU EMA-certified cGMP production complex with a 250,000-litre capacity, and an extensive direct sales network that reaches roughly 100 countries. Its portfolio includes a range of biosimilar antibodies-such as Remsima® (infliximab), Truxima® (rituximab), Herzuma® (trastuzumab) and the newly approved AVTOZMA® (tocilizumab-anoh)-delivered alongside innovative novel biologics.

Through this comprehensive infrastructure, Celltrion Healthcare Ireland Limited supports healthcare providers and patients across Ireland and the broader European market, delivering advanced, affordable medicines that enhance treatment options and improve health outcomes worldwide.